Aetna, Humana, Kaiser Permanente and the UnitedHeath Group will provide data for more than 5 billion medical claims to the Health Care Cost Institute (HCCI) to offer new insights into healthcare costs, utilization, and intensity.
Aetna, Humana, Kaiser Permanente and the UnitedHeath Group will provide data for more than 5 billion medical claims to the Health Care Cost Institute (HCCI) to offer new insights into healthcare costs, utilization, and intensity.
According to the newly formed nonprofit’s press release, “HCCI’s mission is to promote independent research and analysis on the causes of rising U.S. health spending; to provide policy makers, consumers, and researchers with better, more transparent information on what is driving healthcare costs; and to help ensure that, over time, the nation is able to get greater value from its health spending.”
The four insurers’ claim data represents more than $1 trillion of healthcare activity from more than 5,000 hospitals and 1 million service providers from calendar year 2000 through the present. Additionally, the commercial data will be updated regularly to ensure its usefulness for research purposes. Data will be de-identified in accordance with Health Insurance Portability and Accountability Act requirements.
HCCI will provide access to the data to accredited researchers whose proposals meet the organiation’s data and scientific usage standards. Beginning in 2012, HCCI plans to publish its own scorecards and supporting analysis on aggregate trends of healthcare cost and utilization.
Go back to the Managed Healthcare Executive eNews newsletter.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More